<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808351</url>
  </required_header>
  <id_info>
    <org_study_id>NFH20160611</org_study_id>
    <nct_id>NCT02808351</nct_id>
  </id_info>
  <brief_title>Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes</brief_title>
  <official_title>Multicenter Randomized Controlled Study of Berberine for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Renal Insufficient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of cardiac angiography and percutaneous coronary interventions (PCI) has increased
      steadily in recent years. This has resulted in the increasing incidence of contrast-induced
      nephropathy (CIN). Major risk factors for CIN include older age, diabetes mellitus (DM),
      chronic kidney disease(CKD), the concurrent use of nephrotoxic drugs, hemodynamic
      instability, etc. Importantly, DM appears to act as a risk multiplier, meaning that in a
      patient with CKD it amplifies the risk of CIAKI.

      The aim of this multicenter prospective, randomized, controlled study is to evaluate whether
      berberine treatment during and after the perioperative period would reduce the risk of CIN in
      a high-risk population of patients with both DM and CKD undergoing coronary angiography or
      noncoronary angiography, and the influence of such potential benefit on short-term outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-induced nephropathy</measure>
    <time_frame>72 hours</time_frame>
    <description>An absolute increase in serum creatinine (SCr) &gt;=0.5mg/dL（&gt;=44.2μmmol/L）or a &gt;= 25% increase in SCr from baseline to 72 hours after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse renal events</measure>
    <time_frame>30 days</time_frame>
    <description>The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Berberine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blank control of berberine administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <arm_group_label>Berberine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned diagnostic coronary or peripheral artery angiography

          -  Type 2 diabetes mellitus

          -  CKD stages ≥2

          -  Statin naive, or not on statin treatment for at least 14 days

          -  Withdrawal metformin or aminophylline for 48h before angiography

          -  Total iodixanol volume

        Exclusion Criteria:

          -  Hypersensitivity to iodine-containing compounds and berberine

          -  Ketoacidosis

          -  Lactic acidosis

          -  CKD stages 1, 5 (eGFR≥90ml/min per 1.73m2 or eGFR＜15ml/min per 1.73m2)

          -  STEMI

          -  NYHA class IV or hemodynamic instability

          -  Administration of any iodinated contrast medium within 14 days before randomization

          -  LDL-C＜1.82mmol/L（70mg/dL）

          -  Hepatic dysfunction (ALT 3 times greater than upper normal limit)

          -  Thyreoid insufficiency

          -  Renal artery Stenosis(unilateral ＞70％ or bilateral stenosis＞50％)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaoliang Chen</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaoliang Chen, PhD</last_name>
    <phone>+86-25-52208351</phone>
    <email>chmengx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobo Li, PhD</last_name>
    <phone>+86-25-52208358</phone>
    <email>liber0908@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, PhD</last_name>
      <phone>+86-025-52271351</phone>
      <email>chmengx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Kan, MPH</last_name>
      <phone>+86-025-52271398</phone>
      <email>kanjingok@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaobo Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen</investigator_full_name>
    <investigator_title>Director of Cardiology and Cath Lab, Vice President of Nanjing First Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

